MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
40.00
-4.74
-10.59%
After Hours: 40.00 0 0.00% 19:29 03/21 EDT
OPEN
46.00
PREV CLOSE
44.74
HIGH
46.00
LOW
35.46
VOLUME
59.49K
TURNOVER
--
52 WEEK HIGH
54.30
52 WEEK LOW
1.719
MARKET CAP
244.10M
P/E (TTM)
-20.0682
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 2d ago
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
NASDAQ · 2d ago
Monopar a new overweight at Piper Sandler on rare disease asset
Seeking Alpha · 4d ago
Monopar Therapeutics Coverage Assumed by Piper Sandler at Overweight
Dow Jones · 4d ago
Monopar Therapeutics Price Target Announced at $76.00/Share by Piper Sandler
Dow Jones · 4d ago
Piper Sandler Assumes Monopar Therapeutics at Overweight, Announces Price Target of $76
Benzinga · 4d ago
Weekly Report: what happened at MNPR last week (0310-0314)?
Weekly Report · 6d ago
Weekly Report: what happened at MNPR last week (0303-0307)?
Weekly Report · 03/10 11:44
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.